Attention was drawn to disproportionate penalties imposed in some cases, without specifically referring to $500-million fine slapped on Ran...

Ghulam Nabi Azad did some plainspeak with the head of US drug regulator, asserting that Indian drugs should not be treated as spurious.

In the last few months, there's been a spike in "violations" at Indian drug factories, according to data from FDA's Centre for Drug Evaluat...

The decks have been cleared for US-based Mylan Inc's $1.6-billion takeover of Agila Specialties, sending a positive signal to foreign inves...

Indian markets are likely to trade in a range. Here is a list of ten stocks which are likely to remain in focus in morning trade.

Ranbaxy facilities in India are being reviewed after its US arm admitted to manufacturing certain drugs not in conformity with good practic...

The Health min is still taking stock of the Ranbaxy Labs' US-related problems, but has not yet decided to launch any probe on the matter

Pharmaceutical industry today criticised the government's decision to make it mandatory for all foreign investments in existing domestic ph...

The nodal body responsible for approving foreign investments that require government approval would continue to clear foreign acquisitions ...

India has developed a powerful new malaria drug - an alternative to the global drug of choice Artemisinin - that promises to be a major boo...

A high-level inter-ministerial group chaired by the prime minister has decided to continue with the 100% foreign direct investment regime i...

The government on Monday decided to put a filter into foreign direct investment in the pharmaceutical sector.

Worried over the spate of takeover of Indian pharmaceutical companies by multinational firms, the government has set up a panel to study th...

Hetero Drugs has pipped Ranbaxy Laboratories, Cipla, Natco Pharma, Strides Arcolabs and Roche India to bag half the government order to sup...

Share price of drug companies Ranbaxy, Natco and Strides Acrolabs, that make low-priced versions of anti-flu medicine Tamiflu, surged on Tu...

Drugmakers Cipla, Ranbaxy, Hetero and Natco are expected to be in the fray to bag the government's contract to buy 20 million low cost anti...

With about 70% of its stock used up, the government will now procure two crore more pills of oseltamivir—the generic version of Swiss firm ...